Close Menu

NEW YORK (GenomeWeb) – Roche said today that its diagnostics revenues grew 5 percent year over year for the first quarter of 2018, driven by growth across the entire Dx division.

For the three months ended March 31, the Swiss pharmaceutical and diagnostics company reported overall revenues of CHF 13.58 billion ($13.85 billion), up 5 percent from CHF 12.94 billion in Q1 2017.

In diagnostics, Roche reported revenues of CHF 2.91 billion, up from CHF 2.77 billion in 2017.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.